Approvals/TGA/PAVTIDE MDI 50/25 fluticasone propionate 50 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)

Approved

STANDARD

PAVTIDE MDI 50/25 fluticasone propionate 50 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)

GlaxoSmithKline Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: af3f5be3b9544f4f
Company: GlaxoSmithKline Australia Pty Ltd
Type: Standard

Approval Details

Approval Id: af3f5be3b9544f4f
Product Name: PAVTIDE MDI 50/25 fluticasone propionate 50 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)
Artg Id: 208669
Artg Name: PAVTIDE MDI 50/25 fluticasone propionate 50 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)
Sponsor: GlaxoSmithKline Australia Pty Ltd
Company Detail Path: /organization/glaxosmithkline-australia-pty-ltd
Artg Date: 2014-05-07
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Product Information: http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2014-PI-01827-1

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

af3f5be3b9544f4f

Type

Standard

Back to TGA Approvals